What is proximal isovelocity surface area (PISA) and how is it used to quantify valvular regurgitation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is PISA (Proximal Isovelocity Surface Area)?

PISA is a quantitative Doppler echocardiography method that measures the effective regurgitant orifice area (EROA) and regurgitant volume of valvular regurgitation by analyzing the hemispherical flow convergence zone that forms proximal to a regurgitant valve orifice. 1

Fundamental Principle

The PISA method is based on fluid dynamics: as blood flows toward a regurgitant orifice, it forms concentric hemispherical shells with progressively decreasing surface area and increasing velocity. 1 The flow rate through these hemispheric shells equals the flow rate through the regurgitant orifice by the conservation of mass principle.

Calculation Method

The basic formula is:

  • Flow rate = 2πr² × aliasing velocity (where r = radius of the hemispheric shell)
  • EROA = Flow rate / peak regurgitant velocity (by continuous wave Doppler)
  • Regurgitant volume = EROA × time-velocity integral of the regurgitant jet 1

Technical Requirements for Accurate Measurement

To optimize PISA accuracy, you must: 1

  • Magnify the PISA region with sector and depth optimized for color Doppler resolution
  • Align measurement parallel to flow direction to optimize Doppler resolution
  • Shift the Nyquist limit baseline toward the direction of regurgitant flow
  • Use Nyquist limit ranges of 30-40 cm/s for optimal PISA radius measurement
  • Measure at the appropriate time point during systole (for mitral/tricuspid regurgitation)

Critical Limitations You Must Know

PISA has substantial limitations that make it an imperfect tool: 2

Geometric Assumptions

  • Assumes hemispheric flow convergence, which is rarely true in secondary (functional) mitral regurgitation where the PISA region is often hemielliptical 1
  • Systematically underestimates EROA in functional mitral regurgitation because regurgitant orifices are typically crescentic rather than circular 2
  • For elliptical orifices with 3:1 axis ratio, underestimation is approximately 8-10%, but can reach 35% for 10:1 ratios 3

Technical Challenges

  • Errors in radius measurement are squared, resulting in large variance in calculated EROA 2
  • Eccentric jets distort the PISA region due to constraint from atrial walls or valve leaflets, causing falsely increased radius and EROA overestimation 1
  • Difficult to identify the precise location of the valve orifice where measurement should be taken 2
  • High interobserver variability and poor agreement even among experienced observers 2

Physiologic Limitations

  • Regurgitant flow changes during systole - particularly in secondary mitral regurgitation with biphasic flow patterns 2, 4
  • Single-frame PISA measurements don't reflect mean EROA over the entire regurgitant period 2, 4
  • Not validated for multiple jets 5, 2
  • Limited feasibility in aortic regurgitation due to valve calcifications 5

Clinical Application by Valve Type

Mitral and Tricuspid Regurgitation

  • PISA is measurable in 78% of mitral regurgitation cases and 69% of tricuspid regurgitation cases 6
  • Most clinically useful for these atrioventricular valves 5, 6
  • Different severity thresholds apply for primary vs. secondary mitral regurgitation:
    • Severe primary MR: EROA ≥0.4 cm², regurgitant volume ≥60 mL
    • Severe secondary MR: EROA ≥0.2 cm², regurgitant volume ≥30 mL 1

Aortic Regurgitation

  • PISA is measurable in only 26% of aortic regurgitation cases 6
  • When feasible, EROA ≥30 mm² or regurgitant volume ≥60 mL indicates severe AR 5
  • Use parasternal long-axis view for eccentric jets 5

Critical Clinical Pitfalls to Avoid

  1. Never rely on PISA alone - it should not be the sole criterion for determining regurgitation severity 2

  2. Beware of timing errors in non-holosystolic regurgitation:

    • Measuring at peak early systolic flow overestimates severity
    • Measuring at mid-systolic nadir underestimates severity 2, 4
  3. Consider 3D echocardiography when available - it allows direct measurement of vena contracta area and avoids the systematic underestimation inherent to 2D PISA, particularly in functional mitral regurgitation 1, 2

  4. Integrate with other parameters - always use PISA together with vena contracta width, jet characteristics, and chamber dimensions to ensure internal consistency 5, 4

  5. Account for flow constraints - adjacent structures (atrial walls, leaflets) affect PISA shape and accuracy 5, 2

When PISA Works Best

PISA is most accurate for: 7, 8, 6

  • Central (non-eccentric) jets
  • Circular or near-circular orifices
  • Holosystolic regurgitation
  • Moderate to severe regurgitation (large flow convergence zones are easier to measure)

The method becomes increasingly unreliable as jets become more eccentric, orifices more elliptical, and regurgitation milder.

References

Guideline

defining "severe" secondary mitral regurgitation: emphasizing an integrated approach.

Journal of the American College of Cardiology, 2014

Research

Usefulness of color Doppler proximal isovelocity surface area method in quantitating valvular regurgitation.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 1997

Research

Quantification of mitral regurgitant volume by the color Doppler proximal isovelocity surface area method: a clinical study.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 1995

Related Questions

For a patient with a leaky (regurgitant) heart valve, how frequently should follow-up visits and echocardiographic monitoring be scheduled?
What anesthesia plan should be used for bronchoscopy in a patient with severe mitral regurgitation?
What is the recommended treatment for an asymptomatic patient with mild (grade 1+) aortic regurgitation?
Should a patient with mild‑to‑moderate native mitral and tricuspid regurgitation receive antibiotic prophylaxis before a tooth extraction?
Is a 3 g oral dose of amoxicillin indicated before dental treatment for a patient with a prosthetic aortic valve?
A patient receiving supplemental oxygen at 4 L/min experiences a desaturation to 65 % SpO₂ during exertion; how should the oxygen flow be adjusted and what further evaluation is required?
What explains an elevated TSH of 9.96 µIU/mL with a free T4 of 0.97 ng/dL in a patient with liver failure?
What is the recommended duration of doxycycline therapy for cellulitis in an adult?
Which risk factors for prostate cancer indicate that screening should be initiated (e.g., age ≥55 years, African‑American ethnicity, first‑degree relative with early‑onset disease, BRCA1, BRCA2, or HOXB13 mutations, prior high‑grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, or exposure to ionizing radiation or Agent Orange)?
Are doxycycline monohydrate and doxycycline hyclate clinically equivalent for treating cellulitis, and does one formulation have better gastrointestinal tolerability?
What types of sexual dysfunction are associated with fluoxetine (Prozac)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.